Equities analysts expect XOMA Co. (NASDAQ:XOMA) to announce $1.23 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for XOMA’s earnings, with the highest sales estimate coming in at $2.00 million and the lowest estimate coming in at $450,000.00. XOMA posted sales of $800,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 53.8%. The business is expected to announce its next quarterly earnings report on Tuesday, May 4th.

On average, analysts expect that XOMA will report full year sales of $11.60 million for the current financial year, with estimates ranging from $2.30 million to $20.90 million. For the next fiscal year, analysts expect that the business will post sales of $14.37 million, with estimates ranging from $2.84 million to $25.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for XOMA.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, March 9th. The biotechnology company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.00 by ($0.68). XOMA had a negative return on equity of 28.83% and a negative net margin of 102.23%. The company had revenue of $27.58 million for the quarter, compared to analyst estimates of $12.20 million.

A number of research firms have weighed in on XOMA. HC Wainwright increased their price objective on XOMA from $30.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, January 19th. TheStreet raised XOMA from a “d” rating to a “c” rating in a research report on Tuesday. Finally, Zacks Investment Research raised XOMA from a “sell” rating to a “hold” rating in a research report on Tuesday, March 16th.

In other news, Director Bvf Partners L. P/Il sold 569,797 shares of the stock in a transaction that occurred on Wednesday, March 31st. The stock was sold at an average price of $38.36, for a total transaction of $21,857,412.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 9.89% of the company’s stock.

Several hedge funds have recently modified their holdings of XOMA. BlackRock Inc. raised its stake in shares of XOMA by 0.6% during the 3rd quarter. BlackRock Inc. now owns 450,217 shares of the biotechnology company’s stock worth $8,482,000 after buying an additional 2,499 shares in the last quarter. State Street Corp increased its stake in XOMA by 4.5% in the 3rd quarter. State Street Corp now owns 68,482 shares of the biotechnology company’s stock valued at $1,290,000 after purchasing an additional 2,931 shares in the last quarter. Bank of New York Mellon Corp increased its stake in XOMA by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 62,868 shares of the biotechnology company’s stock valued at $2,775,000 after purchasing an additional 3,126 shares in the last quarter. Rhumbline Advisers purchased a new position in XOMA in the 4th quarter valued at approximately $243,000. Finally, Citigroup Inc. increased its stake in XOMA by 105.0% in the 4th quarter. Citigroup Inc. now owns 1,665 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 853 shares in the last quarter. 57.21% of the stock is owned by institutional investors and hedge funds.

XOMA stock traded up $0.60 during mid-day trading on Monday, reaching $39.20. 456 shares of the company were exchanged, compared to its average volume of 56,625. XOMA has a twelve month low of $15.48 and a twelve month high of $46.32. The firm’s 50-day simple moving average is $37.85 and its two-hundred day simple moving average is $33.85. The company has a debt-to-equity ratio of 0.61, a quick ratio of 4.63 and a current ratio of 4.63. The firm has a market cap of $441.12 million, a PE ratio of -35.14 and a beta of 1.26.

XOMA Company Profile

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Recommended Story: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on XOMA (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.